Atrial natriuretic peptide and long acting natriuretic peptide inhibit MEK 1/2 activation in human prostate cancer cells

Anticancer Research

Volumn 27, Issue 6 B, 2007, Pages 3813-3818

  Sun, Ying ^a   Eichelbaum, Ehrentraud J ^a   Wang, Hai ^a   Vesely, David L ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Adenocarcinoma; Atrial natriuretic peptide; Long acting natriuretic peptide; MEK 1 2 kinase; Natriuretic peptides; Prostate neoplasm

Indexed keywords

ANTINEOPLASTIC AGENT; ATRIAL NATRIURETIC FACTOR; CYCLIC GMP; LONG ACTING NATRIURETIC FACTOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION;

ADENOCARCINOMA; AGED; ANIMALS; ANTIBODIES; ANTIBODY SPECIFICITY; ATRIAL NATRIURETIC FACTOR; CELL LINE, TUMOR; CYCLIC GMP; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENZYME ACTIVATION; HUMANS; MALE; MAP KINASE KINASE 1; MAP KINASE KINASE 2; MICE; MICE, NUDE; PEPTIDE FRAGMENTS; PHOSPHORYLATION; PROSTATIC NEOPLASMS;

EID: 37349025338     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Scholl FA, Dumesic PA and Khavari PA: Effects of active MEK 1 expression in vivo. Cancer Lett 230: 1-5, 2005.
2. McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE, Navolanic PM, Terrian DM, Franklin RA, D'Assoro AB, Salisbury JL, Mazzario MC, Stivala F and Libra M: Roles of the Raf/MEK/ERK and P13K/PTN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 46: 249-279, 2006.
3. Crews CM, Alessandrini A and Erikson RL: The primary structure of MEK, a protein kinase that phosphorylates the ERK gene product. Science 258: 478-480, 1992.
4. Wu J, Harrison JK, Dent P, Lynch KR, Weber MJ and Sturgill TW: Identification and characterization of a new mammalian mitogen-activated protein kinase kinase MKK-2. Mol Cell Biol 13: 4539-4548, 1993.
5. Sun Y, Eichelbaum EJ, Wang H and Vesely DL: Atrial natriuretic peptide and long acting natriuretic peptide inhibit activation of ERK 1/2 in human prostate cancer cells. Anticancer Res 26: 4193-4195, 2006.
6. Waldman SA, Rapoport RM and Murad F: Atrial natriuretic factor selectively activates membranous guanylate cyclase and elevates cyclic GMP in rat tissues. J Biol Chem 259: 14332-14334, 1984.
7. Vesely DL: Signal transduction: Activation of guanylate cyclase-cyclic guanosine-3′-5′ monophosphate system by hormones and free radicals. Am J Med Sci 314: 311-323, 1997.
8. Stone KR, Mickey DD, Wunderli H, Mickey GH and Paulson DF: Isolation of a human prostate carcinoma cell line (DU-145). Int J Cancer 21: 274-281, 1978.
9. Vesely BA, Alli AA, Song S, Gower WR Jr, Sanchez-Ramos J and Vesely DL: Four peptide hormones specific decrease (up to 97%) of human prostate carcinoma cells. Eur J Clin Invest 35: 700-710, 2005.
10. Vesely BA, McAfee Q, Gower WR Jr and Vesely DL: Four peptides decrease the number of human pancreatic adenocarcinoma cells. Eur J Clin Invest 33: 998-1005, 2003.
11. Vesely BA, Song S, Sanchez-Ramos J, Fitz SR, Solivan SM, Gower WR Jr and Vesely DL: Four peptide hormones decrease the number of human breast adenocarcinoma cells. Eur J Clin Invest 35: 60-69, 2005.
12. Gower WR Jr, Vesely BA, Alli AA and Vesely DL: Four peptides decrease human colon adenocarcinoma cell number and DNA synthesis via guanosine 3′,5′-cyclic monophosphate. Int J Gastrointestinal Cancer 36: 77-88, 2005.
13. Vesely BA, Fitz SR, Gower WR Jr and Vesely DL: Vessel dilator: Most potent of the atrial natriuretic peptides in decreasing the number and DNA synthesis of squamous lung cancer cells. Cancer Lett 232: 226-231, 2006.
14. Vesely BA, Song S, Sanchez-Ramos J, Fitz SR, Alli A, Solivan SM, Gower WR Jr and Vesely DL: Five cardiac hormones decrease the number of human small-cell cancer cells. Eur J Clin Invest 35: 388-398, 2005.
15. Vesely BA, Eichelbaum EJ, Alli AA, Sun Y, Gower WR Jr and Vesely DL: Urodilatin and four cardiac hormones decrease human renal carcinoma cell number. Eur J Clin Invest 36: 810-819, 2006.
16. Vesely BA, Eichelbaum EJ, Alli AA, Sun Y, Gower WR Jr and Vesely DL: Four cardiac hormones cause cell death in 81% of human ovarian adenocarcinoma cells. Cancer Therapy 5: 97-104, 2007.
17. Vesely BA, Eichelbaum EJ, Alli AA, Sun Y, Gower WR Jr and Vesely DL: Four cardiac hormones cause cell death of melanoma cells and inhibit their DNA synthesis. Am J Med Sci, in press, 2007.
18. Vesely DL, Clark LC, Garces AH, McAfee QW, Soto J and Gower WR Jr: Novel therapeutic approach for cancer using four cardiovascular hormones. Eur J Clin Invest 34: 674-682, 2004.
19. Vesely DL, Eichelbaum EJ, Sun Y, Alli AA, Vesely BA, Luther SL and Gower WR Jr: Elimination of up to 80% of human pancreatic adenocarcinomas in athymic mice by cardiac hormones. In Vivo 21: 445-451, 2007.